There are no interventional cardiologist listening. There are no cardiologists listing. We got this awesome med student but that’s it. Cardiology trails needs better marketing. No money I know . guys great talk. Please don’t stop.
Thank you Dr. Foy for citing some basic common sense free market principles for the discussion. You were very kind to Dr. Mandrola when you questioned his assessment of the significance of the tiny difference in a secondary endpoint that can vary for many reasons (revascularization) when the considerably harder primaries were null. I think that all the studies in this series show that the drug eluting stents show no significant advantage over the bare metal and that the several reasons why they are dominating the market were astutely assessed by all of you.
thank you! great discussion
There are no interventional cardiologist listening. There are no cardiologists listing. We got this awesome med student but that’s it. Cardiology trails needs better marketing. No money I know . guys great talk. Please don’t stop.
Thank you Dr. Foy for citing some basic common sense free market principles for the discussion. You were very kind to Dr. Mandrola when you questioned his assessment of the significance of the tiny difference in a secondary endpoint that can vary for many reasons (revascularization) when the considerably harder primaries were null. I think that all the studies in this series show that the drug eluting stents show no significant advantage over the bare metal and that the several reasons why they are dominating the market were astutely assessed by all of you.